**IN THE UNITED STATES DISTRICT COURT**

**FOR THE DISTRICT OF DELAWARE**

| | |
|---|---|
| **IN RE: OZEMPIC (SEMAGLUTIDE) PATENT LITIGATION** | No. 22-md-3038-CFC |
| **NOVO NORDISK INC. and NOVO NORDISK A/S,**<br>Plaintiffs/Counterclaim Defendants,<br>v.<br>**RIO BIOPHARMACEUTICALS INC. et al.**,<br>Defendants/Counterclaim Plaintiffs. | No. 22-cv-294-CFC<br>CONSOLIDATED<br>**ANDA CASE** |
| **NOVO NORDISK INC. and NOVO NORDISK A/S,**<br>Plaintiffs/Counterclaim Defendants,<br>v.<br>**MYLAN PHARMACEUTICALS INC.,**<br>Defendant/Counterclaim Plaintiff. | No. 22-cv-1040-CFC<br>**ANDA CASE** |

# Opening Expert Report of Dr. John Bantle Regarding Invalidity of U.S. Patent No. 10,335,462

Novo Nordisk Exhibit 2024
Dr. Reddy's Lab'ys, Inc. v. Novo Nordisk A/S
IPR2024-00009
Page 00001

## TABLE OF CONTENTS

**Page**


I. Qualifications and Background ..... 1
A. Education and Experience; Prior Testimony ..... 1
B. Basis for Opinions and Materials Considered ..... 4
C. Retention and Compensation ..... 4
II. Summary of Opinions ..... 4
III. Legal Standards ..... 7
IV. Person of Ordinary Skill in the Art ..... 9
V. The '462 Patent and Its Asserted Claims ..... 11
VI. Claim Construction ..... 19
VII. Background on Diabetes and the use of GLP-1 Derivatives for the Treatment of Diabetes ..... 20
A. Diabetes Generally ..... 20
B. Diabetes Treatment ..... 22
C. The Use of GLP-1 Derivatives to Treat Diabetes ..... 25
D. Use of Liraglutide to Treat Diabetes ..... 27
E. Extended-Use GLP-1 Receptor Agonists ..... 32
VIII. Scope and Content of the Prior Art ..... 41
A. Lovshin ..... 43
B. Madsbad ..... 45
C. U.S. Patent No. 8,114,833 ..... 47
D. WO 2006/097537 ..... 54
E. WO 2011/138421 ..... 60
F. NCT00696657 Semaglutide Clinical Trial Record ..... 64
1. Clinical Trial No. NCT00696657 ..... 64
2. ClinicalTrials.gov is a Part of the POSA's Knowledge ..... 66
G. Other Technical Background Forming the POSA's Knowledge ..... 73




Novo Nordisk Exhibit 2024
Dr. Reddy's Lab'ys, Inc. v. Novo Nordisk A/S
IPR2024-00009
Page 00002

**TABLE OF CONTENTS**
(continued)

**Page**


1. Clinical Trial No. NCT00851773 ..... 73
2. Bhansali ..... 79
3. Drucker 2003 ..... 84
4. Holst 2004 ..... 85
5. Knudsen 2001 ..... 89
6. Knudsen 2004 ..... 93
7. Knudsen patent (U.S. Patent No. 6,268,343) ..... 98
8. Lund ..... 103
9. U.S. Patent Application Pub. No. US2007/0010424 ..... 103
10. Victoza label ..... 108
11. WO 03/002136 ..... 111
12. Additional prior art and references ..... 116

IX. Invalidity of the Asserted Claims of the '462 Patent ..... 117

A. Each of WO '421, NCT00696657, and Lovshin anticipated claims 1 and 3 ..... 117

1. WO '421 ..... 118
2. NCT00696657 ..... 126
3. Lovshin ..... 133

B. All Asserted Claims of the '462 Patent Would Have Been Obvious Over the Prior Art ..... 141

1. Claims 1, 3, 4, 5, and 7 of the '462 patent would have been obvious over WO '421, NCT00696657, WO '537 and/or Lovshin, optionally in view of one or more of the '833 Patent and Madsbad ..... 142
2. Claims 1, 3, 4, 5, and 7 of the '462 patent would have been obvious over WO '421 alone or in view of the '833 patent ..... 168
3. Claims 1, 3, 4, 5, and 7 of the '462 patent would have been obvious over WO '537 in view of Lovshin ..... 181




Novo Nordisk Exhibit 2024
Dr. Reddy's Lab'ys, Inc. v. Novo Nordisk A/S
IPR2024-00009
Page 00003

## TABLE OF CONTENTS
(continued)

**Page**

C. All Claims of the '462 Patent Are Invalid for Lack of Written Description if They Would not have been Obvious .....194

X. Reservation of Rights .....202



Novo Nordisk Exhibit 2024
Dr. Reddy's Lab'ys, Inc. v. Novo Nordisk A/S
IPR2024-00009
Page 00004

## TABLE OF ABBREVIATIONS

| Full Name of Cited Reference | Abbreviation |
|---|---|
| U.S. Patent Application Pub. No. US2011/0166321 | '321 publication |
| U.S. Patent Application Pub. No. US2007/0010424 | '424 publication |
| U.S. Patent No. 10,335,462<br>NN-OZEM-000000071-95 | '462 patent |
| U.S. Patent No. 10,335,462 file history<br>NN-OZEM-000003820-4446 | '462 file history |
| U.S. Patent No. 5,512,549 | '549 patent |
| U.S. Patent No. 8,114,833<br>SEMA(JDG)_0000447-468 | '833 patent |
| Banting, *The Internal Secretion of the Pancreas,* 7 J. LAB. CLINICAL MED. 251 (1922) | Banting |
| Bell, *Hamster Preproglucagon Contains the Sequence of Glucagon and Two Related Peptides*, 302 NATURE 716 (1983) | Bell |
| Bhansali, *Historical Overview of Incretin Based Therapies*, 58 J. ASSOC. OF PHYSICIANS OF INDIA 10 (2010)<br>SEMA(JDG)_0000014-18 | Bhansali |
| Highlights of Prescribing Information: Bydureon, Rev. 1/2012<br>https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/<br>022200Orig1s000lbledt.pdf (last accessed Feb. 26, 2024) | Bydureon label |
| Highlights of Prescribing Information: Byetta, Rev. 10/2009<br>https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/<br>021773s9s11s18s22s25lbl.pdf (last accessed Feb. 26, 2024) | Byetta label |
| *ClinicalTrials.gov Background*, CLINICALTRIALS.GOV, https://clinicaltrials.gov/about-site/about-ctg (last visited Mar. 15, 2024) | ClinicalTrials.gov Background |



Novo Nordisk Exhibit 2024
Dr. Reddy's Lab'ys, Inc. v. Novo Nordisk A/S
IPR2024-00009
Page 00005

## TABLE OF ABBREVIATIONS
(continued)

| Full Name of Cited Reference | Abbreviation |
|---|---|
| Drab, *Incretin-Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects*, 30 PHARMACOTHERAPY 609 (2010) | Drab |
| Drucker, *Enhancing Incretin Action for the Treatment of Type 2 Diabetes*, 26 DIABETES CARE 2929 (2003) | Drucker 2003 |
| Drucker, *The Incretin System: Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes*, 368 LANCET 1696 (2006) | Drucker 2006a |
| Drucker, *The Biology Of Incretin Hormones*, 3 CELL METABOLISM 153 (2006) | Drucker 2006b |
| Glaesner, *Engineering and Characterization of the Long-Acting Glucagon-Like Peptide-1 Analogue LY2189265, an Fc Fusion Protein*, 26 DIABETES/METABOLISM RSCH. & REV. 287 (2010) | Glaesner |
| HARRISON'S PRINCIPLES OF INTERNAL MED., Chapter 338 (Fauci et al. eds. 17th ed. 2008) | Harrison's |
| *Award: ClinicalTrials.gov*, https://ash.harvard.edu/news/clinicaltrialsgov (last visited Mar. 15, 2024) | Harvard Award |
| Holst, *Truncated Glucagon-like Peptide I, an Insulin-Releasing Hormone from the Distal Gut*, 211 FEBS LETTERS 169 (1987) | Holst 1987 |
| Holst, *Glucagon-Like Peptide 1 and Inhibitors of Dipeptidyl Peptidase IV in the Treatment of Type 2 Diabetes Mellitus*, 4 CURRENT OP. IN PHARMACOLOGY 589 (2004) | Holst 2004 |
| Jimenez-Solem, *Dulaglutide, a Long-Acting GLP-1 Analog Fused with an Fc Antibody Fragment for the Potential Treatment of Type 2 Diabetes*, 12 CURRENT OP. IN MOLECULAR THERAPEUTICS 790 (2010) | Jimenez-Solem |
| Kim, *Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects with Type 2 Diabetes*, 30 DIABETES CARE 1487 (2007) SEMA(JDG)_0002583-2589 | Kim |



Novo Nordisk Exhibit 2024
Dr. Reddy's Lab'ys, Inc. v. Novo Nordisk A/S
IPR2024-00009
Page 00006

## TABLE OF ABBREVIATIONS
(continued)

| Full Name of Cited Reference | Abbreviation |
|---|---|
| Knudsen, *GLP-1 Derivatives as Novel Compounds for the Treatment of Type 2 Diabetes: Selection of NN2211 for Clinical Development*, 26 DRUGS OF THE FUTURE 677 (2001) | Knudsen 2001 |
| Knudsen, *Glucagon-like Peptide-1: The Basis of a New Class of Treatment for Type 2 Diabetes*, 47 J. MED. CHEMISTRY 4128 (2004) | Knudsen 2004 |
| Knudsen, *Liraglutide, a GLP-1 Analogue to Treat Diabetes* in ANALOGUE-BASED DRUG DISCOVERY II (Fischer & Ganellin eds. 2010) | Knudsen 2010a |
| Knudsen, *Liraglutide: The Therapeutic Promise from Animal Models*, 64 INT'L J. CLINICAL PRACTICE 4 (2010) | Knudsen 2010b |
| U.S. Patent No. 6,268,343<br>SEMA(JDG)_0000487-624 | Knudsen patent |
| Lovshin, *Incretin-Based Therapies for Type 2 Diabetes Mellitus*, 5 NATURE REV. ENDOCRINOLOGY 262 (2009)<br>SEMA(JDG)_0002250-58 | Lovshin |
| Lund, *Emerging GLP-1 Receptor Agonists*, 16 EXPERT OP. ON EMERGING DRUGS 607 (2011) | Lund |
| Madsbad, *An Overview of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists—Available Efficacy and Safety Data and Perspectives for the Future*, 13 DIABETES, OBESITY & METABOLISM 394 (2011)<br>SEMA(JDG)_0002439-52 | Madsbad |
| Marre, *GLP-1 Receptor Agonists Today*, 93 DIABETES RSCH. & CLINICAL PRAC. 317 (2011) | Marre |
| Mojsov, *Insulinotropin: Glucagon-like Peptide I (7-37) Co-encoded in the Glucagon Gene is a Potent Simulator of Insulin Release in the Perfused Rat Pancreas*, 79 J. CLIN. INVEST. 616 (1987) | Mojsov |
| Monami, *Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis*, 2012 EXPERIMENTAL DIABETES RSCH. 1 (2012) | Monami |



Novo Nordisk Exhibit 2024
Dr. Reddy's Lab'ys, Inc. v. Novo Nordisk A/S
IPR2024-00009
Page 00007

## TABLE OF ABBREVIATIONS
(continued)

| Full Name of Cited Reference | Abbreviation |
|---|---|
| *NCT00167115*, CLINICALTRIALS.GOV, https://www.clinicaltrials.gov/ct2/show/NCT00167115 (last visited Mar. 15, 2024) | NCT00167115 |
| *NCT01933490*, CLINICALTRIALS.GOV, https://www.clinicaltrials.gov/ct2/show/NCT01933490 (last visited Mar. 15, 2024) | NCT01933490 |
| Clinical Trial No. NCT00696657 | NCT00696657 |
| Clinical Trial No. NCT00851773 | NCT00851773 |
| Nielsen, *Pharmacology of Exenatide (Synthetic Exendin-4): A Potential Therapeutic for Improved Glycemic Control of Type 2 Diabetes*, 117 REGUL. PEPTIDES 77 (2004) | Nielsen |
| Novo Nordisk Pipeline – Semaglutide (2010-2011) http://novonordisk.com:80/science/pipeline /rd_pipeline.asp?showid=7 (Internet Archive captures) | Novo Pipeline |
| Seino, *Dose-Dependent Improvement in Glycemia with Once-Daily Liraglutide without Hypoglycemia or Weight Gain: A Double-Blind, Randomized, Controlled Trial in Japanese Patients with Type 2 Diabetes*, 81 DIABETES RSCH. & CLINICAL PRACTICE 161 (2008) | Seino |
| Tamimi, *Drug Development: From Concept to Marketing!*, 113 NEPHRON CLINICAL PRACTICE c125 (2009) | Tamimi |
| Tasneem, *The Database for Aggregate Analysis of ClinicalTrials.gov (AACT) and Subsequent Regrouping by Clinical Specialty*, 7(3) PLOS ONE 1 (2012) | Tasneem |
| *Victoza*, PHYSICIANS' DESK REFERENCE (65th ed. 2011) | Victoza label |
| Vilsbøll, *Glucagon-Like Peptide-1 and Diabetes Treatment*, 21 INTERNATIONAL DIABETES MONITOR 1 (2009) | Vilsbøll |
| Int'l Patent Application Pub. No. WO 03/002136 SEMA(JDG)_0000373-422 | WO '136 |
| Int'l Patent Application Pub. No. WO 2011/058193 | WO '193 |
| Int'l Patent Application Pub. No. WO 2011/073328 | WO '328 |



Novo Nordisk Exhibit 2024
Dr. Reddy's Lab'ys, Inc. v. Novo Nordisk A/S
IPR2024-00009
Page 00008

## TABLE OF ABBREVIATIONS
(continued)

| Full Name of Cited Reference | Abbreviation |
|---|---|
| Int'l Patent Application Pub. No. WO 2011/138421 SEMA(JDG)_0002087-2158 | WO '421 |
| Int'l Patent Application Publication No. WO 91/11457 | WO '457 |
| Int'l Patent Application Pub. No. WO 2006/097537 SEMA(JDG)_0002453-2528 | WO '537 |
| Zarin, *The ClinicalTrials.gov Results Database—Update and Key Issues*, 364 NEW ENGL. J. MED. 852 (2011) | Zarin |



Novo Nordisk Exhibit 2024
Dr. Reddy's Lab'ys, Inc. v. Novo Nordisk A/S
IPR2024-00009
Page 00009

1. My name is John P. Bantle, M.D. I have been retained by Mylan Pharmaceuticals Inc., Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc., Rio Biopharmaceuticals Inc. and EMS S/A; Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc.; and Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Zydus Lifesciences Limited (collectively, "defendants"), to provide my expert opinions regarding the invalidity of the asserted claims of U.S. Patent No. 10,335,462 ("'462 patent"), which I understand to be claims 1, 3, 4, 5, and 7.

## I. QUALIFICATIONS AND BACKGROUND

### A. Education and Experience; Prior Testimony

2. I am a medical endocrinologist and Professor Emeritus of Medicine in the Division of Endocrinology and Diabetes, Department of Medicine, at the University of Minnesota. I have substantial experience in clinical research, treatment of patients, and academic publications in the field of the treatment of diabetes and related conditions.

3. I earned a Bachelor of Science degree in 1970 from the University of Minnesota and a Doctor of Medicine degree in 1972 from the University of Minnesota Medical School. I completed an internship at Cleveland Metropolitan General Hospital in 1973; residencies in internal medicine at the Mayo Clinic in Rochester, Minnesota, and Dunedin Public Hospital in



Novo Nordisk Exhibit 2024
Dr. Reddy's Lab'ys, Inc. v. Novo Nordisk A/S
IPR2024-00009
Page 00010

any documents the parties have exchanged. Additionally, I may rely on visual aids and/or demonstrative exhibits that I prepare or have prepared on my behalf based upon my opinions.

I declare that all statements made herein of my knowledge are true, and that all statements made on information and belief are believed to be true, and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.

Dated: March 19, 2024 By: John Bantle, MD

Dr. John Bantle



Novo Nordisk Exhibit 2024
Dr. Reddy's Lab'ys, Inc. v. Novo Nordisk A/S
IPR2024-00009
Page 00011